 |
|
New study reveals structure of E. coli multidrug transporter protein
May 05, 2006Determination could aid in fight against drug-resistant bacteria
This new study could potentially help researchers find new ways to avoid the problem of multidrug resistance and enhance the potency of existing drug compounds.
The study is being published in ScienceXpress, an advance online edition of the journal Science, on May 5.
"The development of antibiotics to treat infectious disease is being seriously undermined by the emergence of drug-resistant bacteria," says Geoffrey A. Chang, Ph.D., a Scripps Research associate professor and a member of the Skaggs Institute for Chemical Biology, who led the study. "Multidrug resistance develops in part through the expulsion of drugs by integral membrane transporters like EmrD. Determining the structure of this transporter will add significantly to our general understanding of the mechanism of drug transport through the cell membrane and provide the structural basis for how these proteins go about selecting specific drugs to expel."
Multidrug resistant bacterial infections raise the cost of medical treatment and are far more expensive than treating normal infections. Treating drug-resistant tuberculosis, for example, requires so-called second-line drugs if standard treatment fails. According to the Centers for Disease Control, second-line drugs can cost as much as "$33,000 per patient in industrialized countries compared to $84 for first-line drugs." In addition, the centers noted, second-line drugs need to be taken for longer periods of time-from 18 to 36 months-and may require substantial patient monitoring, making these treatments difficult if not impossible to "be available in many of the resource-poor nations where drug-resistant tuberculosis is emerging."
EmrD belongs to the Major Facilitator Superfamily, a group of transporters among the most prevalent in microbial genomes. These transporters are distinctive in their ability to recognize and expel a highly diverse range of amphipathic compounds. Amphipathic molecules contain both hydrophobic and hydrophilic groups-molecules that repel or are attracted to water, respectively.
The x-ray structure of the EmrD transporter-determined with data collected at the Stanford University Synchrotron Radiation Laboratory and the Advanced Light Source at the University of California, Berkeley-revealed an interior composed primarily of hydrophobic residues. This finding is consistent with its role of transporting hydrophobic or lipophilic molecules-and similar to the interior of another multidrug transporter, EmrE, which Chang and his colleagues uncovered in a study that was published last year in the journal Science.
This internal cavity is the "most notable difference" between EmrD and most non-Major Facilitator Superfamily multidrug transporters that, the new study noted, typically transport "a relatively narrow range of structurally related" compounds. The hydrophobic residues in the EmrD internal cavity are likely to contribute to the general mechanism transporting various compounds through the cell membrane, and may play "an important role in dictating a level of drug specificity" through a number of molecular interactions.
The study also suggests that EmrD intercepts and binds cyanide m-chlorophenyl hydrazone, a known efflux pump inhibitor, before it reaches the cell cytoplasm. This binding is likely facilitated by hydrophobic interactions within the internal cavity of EmrD. The researchers speculate that cyanide m-chlorophenyl hydrazone is either expelled from the bacterial cell or into the periplasmic space-the space between the outer membrane and the plasma membrane in gram-negative bacteria like E. coli.
"While EmrD and EmrE are completely different proteins from different molecular families," Chang said, "both are multidrug transporters that help bacteria develop multidrug resistance. Together with MsbA, another MDR structure that our laboratory is studying, this new x-ray structure adds another important view of some general structural features across multi-drug resistant transporter families."
Other authors of the study include Yong Yin, Xiao He, Paul Szewczyk, and That Nguyen of The Scripps Research Institute.
Scripps Research Institute
"The development of antibiotics to treat infectious disease is being seriously undermined by the emergence of drug-resistant bacteria," says Geoffrey A. Chang, Ph.D., a Scripps Research associate professor and a member of the Skaggs Institute for Chemical Biology, who led the study. "Multidrug resistance develops in part through the expulsion of drugs by integral membrane transporters like EmrD. Determining the structure of this transporter will add significantly to our general understanding of the mechanism of drug transport through the cell membrane and provide the structural basis for how these proteins go about selecting specific drugs to expel."
Multidrug resistant bacterial infections raise the cost of medical treatment and are far more expensive than treating normal infections. Treating drug-resistant tuberculosis, for example, requires so-called second-line drugs if standard treatment fails. According to the Centers for Disease Control, second-line drugs can cost as much as "$33,000 per patient in industrialized countries compared to $84 for first-line drugs." In addition, the centers noted, second-line drugs need to be taken for longer periods of time-from 18 to 36 months-and may require substantial patient monitoring, making these treatments difficult if not impossible to "be available in many of the resource-poor nations where drug-resistant tuberculosis is emerging."
EmrD belongs to the Major Facilitator Superfamily, a group of transporters among the most prevalent in microbial genomes. These transporters are distinctive in their ability to recognize and expel a highly diverse range of amphipathic compounds. Amphipathic molecules contain both hydrophobic and hydrophilic groups-molecules that repel or are attracted to water, respectively.
The x-ray structure of the EmrD transporter-determined with data collected at the Stanford University Synchrotron Radiation Laboratory and the Advanced Light Source at the University of California, Berkeley-revealed an interior composed primarily of hydrophobic residues. This finding is consistent with its role of transporting hydrophobic or lipophilic molecules-and similar to the interior of another multidrug transporter, EmrE, which Chang and his colleagues uncovered in a study that was published last year in the journal Science.
This internal cavity is the "most notable difference" between EmrD and most non-Major Facilitator Superfamily multidrug transporters that, the new study noted, typically transport "a relatively narrow range of structurally related" compounds. The hydrophobic residues in the EmrD internal cavity are likely to contribute to the general mechanism transporting various compounds through the cell membrane, and may play "an important role in dictating a level of drug specificity" through a number of molecular interactions.
The study also suggests that EmrD intercepts and binds cyanide m-chlorophenyl hydrazone, a known efflux pump inhibitor, before it reaches the cell cytoplasm. This binding is likely facilitated by hydrophobic interactions within the internal cavity of EmrD. The researchers speculate that cyanide m-chlorophenyl hydrazone is either expelled from the bacterial cell or into the periplasmic space-the space between the outer membrane and the plasma membrane in gram-negative bacteria like E. coli.
"While EmrD and EmrE are completely different proteins from different molecular families," Chang said, "both are multidrug transporters that help bacteria develop multidrug resistance. Together with MsbA, another MDR structure that our laboratory is studying, this new x-ray structure adds another important view of some general structural features across multi-drug resistant transporter families."
Other authors of the study include Yong Yin, Xiao He, Paul Szewczyk, and That Nguyen of The Scripps Research Institute.
Scripps Research Institute
Drug Resistance Current Events and Drug Resistance News RSSScientists decode genome of parasite that causes relapsing malaria
Scientists have deciphered the complete genetic sequence of the parasite Plasmodium vivax, the leading cause of relapsing malaria, and compared it with the genomes of other species of malaria parasites.
MU scientists 'see' how HIV matures into an infection
After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death.
Breast cancer treatment resistance linked to signaling pathway
Activation of the Src signaling pathway may cause resistance to standard medical treatment in some patients with breast cancer, and inhibition of this pathway holds the potential to overcome that resistance, according to data presented here at the American Association for Cancer Research Molecular Diagnostics in Cancer Therapeutic Development meeting.
Best way to treat malaria: Avoid using same drug for everyone, scientists say
A team of scientists employing a sophisticated computer model pioneered at Princeton University and Resources for the Future has found that many governments worldwide are recommending the wrong kind of malaria treatment.
Study: Delaying evolution of drug resistance in malaria parasite possible
There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.
ABC-transporters expressed on endothelial cell membranes efflux anti-HIV drugs
Researchers at Tulane University Medical Center in New Orleans (USA) have discovered that drug-efflux pumps, belonging to the ATP-binding cassette (ABC) transporter family, are constitutively expressed on vascular endothelial cells.
CSHL scientists identify new drug target against virulent type of breast cancer
Tumor cells in a particular subset of breast cancer patients churn out too much of a protein called ErbB2 -- also often called HER2 -- which drives the cells to proliferate unchecked. Patients unlucky enough to be in this group -- about one in four -- have poorer prognoses and clinical outcomes than those who don't.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
Treatment outcomes highlight dangers of extensively drug-resistant tuberculosis
In a retrospective study of 174 tuberculosis patients treated at National Jewish Health (formerly National Jewish Medical and Research Center), patients with extensively-drug-resistant tuberculosis (XDR-TB) were almost eight times as likely to die as patients with multi-drug resistant tuberculosis (MDR-TB).
More Drug Resistance Current Events and Drug Resistance News Articles
 | Drug Resistance in Epilepsy: Lessons from Oncology - No. 243 (Novartis Foundation Symposia) by Novartis Foundation The object of this book is to gather together workers in the fields of epilepsy, those concerned with the basic science of resistance and the blood-brain barrier, and those with clinical experience of drug resistance in cancer, with a view to stimulating further work on drug resistance in epilepsy. Whilst resistance in cancer has been extensively studied, and trials of reversal of resistance have... |
| Chemotherapy and Drug Resistance in Malaria (Chemotherapy & Drug Resistance in Malaria) by Wallace Peters | |
 | Drug Resistance in Leukemia and Lymphoma III (Advances in Experimental Medicine and Biology) This volume covers all important aspects of drug resistance in leukemia and lymphoma. General mechanisms of resistance are discussed, including the drug resistance related proteins, MRP (multi drug resistance protein) and LRP (lung resistance protein), and the role of glutathione and glutathione-S-transferases, as well as drug-specific mechanisms of resistance, apoptosis and its regulators... |
| Drug resistance of microorganisms by Robert Julius Schnitzer | |
 | Cancer Drug Resistance (Cancer Drug Discovery and Development) Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug... |
 | Bacterial Resistance to Antimicrobials, Second Edition The enormous genetic flexibility of bacteria jeopardizes the usefulness of currently available antibiotics, and requires new approaches to antibiotic discovery and development. Antimicrobial resistance can be acquired in a short time frame, both by genetic mutation and by direct transfer of resistance genes across genus and species boundaries. Understanding mechanisms of resistance is crucial... |
 | Cytotoxic Drug Resistance Mechanisms (Methods in Molecular Medicine) (Methods in Molecular Medicine) Leading clinical and laboratory scientists describe cutting-edge methods for examining the mechanisms of cellular resistance to anticancer cytotoxics in human tumors. The protocols contain detailed instructions and extensive troubleshooting tips that allow researchers effectively to study a wide variety of drug resistance mechanisms, including aspects of drug-induced cell death, drug... |
 | Frontiers in Antimicrobial Resistance: A Tribute to Stuart B. Levy Frontiers in Antimicrobial Resistance: a Tribute to Stuart B. Levy offers a unique examination of the state of antimicrobial and anticancer drug resistance. The body of the text features descriptions of the major mechanisms and the epidemiology of resistance and explores the current policy and education efforts toward maintaining drug efficacy. Special emphasis is placed on those areas... |
 | Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures (Infectious Disease and Therapy) This publication provides a state-of-the-art overview of key issues related to antimicrobial resistance, including a focus on key pathogens causing common healthcare-associated and community-acquired infections. The epidemiology and therapeutic considerations of these antimicrobial resistant organisms are discussed, as well as the clinical and health economic impact of infections caused by them.... |
 | Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy (Cancer Drug Discovery and Development) (Cancer Drug Discovery and Development) Cancer chemotherapy can be traced back to the 1940 s and since then the world has witnessed the discovery and the important application of several new drugs. The successes of combination chemotherapy suggested that all cancers can be treated provided that the correct combination of drugs at the correct doses and correct intervals are established. However, with time, tumor cells develop mechanisms... |
| © 2008 BrightSurf.com |